Company intelligence / Profile preview
Ilonov
Franceilonov-diabetes.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Ilonov’s lead candidate, ILV-001, has shown preclinical safety and efficacy in in vivo models of Type 1 and Type 2 Diabetes, particularly for preserving and stimulating pancreatic beta cell function and restoring tissue insulin sensitivity.
- Therapeutic areas
- EndocrinologyMetabolic Disorders
- Modalities
- BiologicBiological product
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
CeeD (European Diabetes Study Center)
Beyond the preview
Go deeper on Ilonov.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ilonov.